Peptide deformylase inhibitors

1. A compound according to formula (I):

wherein:

X is selected from the group consisting of —C(O)OC 1-3 alkyl, —OR1, —NR1R6, —C(O)NR1R6, or —C(O)R6;

R1 is selected from the group consisting of hydrogen, C 1-6 alkyl, unsubstituted or substituted by one or more moieties selected from the group consisting of alcohol, ether, amine, amide, carboxylic acid, lactam, Ar, —C 1-2 alkyl Ar, C 0-2 alkylpiperidin-4-yl, substituted on nitrogen with R7, and C 0-2 alkylpyrrolidin-3-yl, substituted on nitrogen with R7 or C 0-2 morpholine);

R6 is selected from the group consisting of hydrogen, C 1-6 alkyl, unsubstituted or substituted by one or more moieties selected from the group consisting of halide, alcohol, ether, amine and amide;

or, R1 and R6 taken together may constitute a 5 or 6 member cyclic system which may contain an O or an optionally substituted N;

Ar is selected from the group consisting of phenyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, and pyrimidyl, all of which may be unsubstituted or substituted by one or more R4 or R5 groups;

R2 is selected from the group consisting of I, Br, Cl, isopropyl and tert-butyl;

R3 is selected from the group consisting of H, I, Br, Cl, isopropyl, tert-butyl and Z-R8;

Z is selected from the group consisting of O, —NH, —NHC(O), —C(O)NH, —SO 2 NH, —CONHSO 2 , —CONHNHCO and —CH 2 ;

R4 and R5 are independently selected from the group consisting of hydrogen, —OR9, —CN, F, Cl, Br, I, —CO 2 H, —C(O)NR1R6, —NR6COR6, —NH 2 , and —C 1-4 alkyl which may be unsubstituted or substituted by one or more alcohol, amine, amide or carboxylic acid moieties;

R9 is H, —CH 3 or —CF3;

R7 is selected from the group consisting of hydrogen, —C 1-4 acyl and —C 1-4 alkoxycarbonyl;

R8 is selected from the group consisting of C 1-4 alkyl which may be unsubstituted or substituted by one or more alcohol, amine, amide, carboxylic acid, aryl or carbocycle.

2. A compound according to claim 1 selected from the group consisting of:

N-Hydroxy-N-(4-methoxy-3,5-dimethylbenzyl)formamide;

N-(3,5-Diisopropyl-4-methoxybenzyl)-N-hydroxyformamide;

Methyl 2,6-dichloro-4-(N-formyl-N-hydroxyaminomethyl)benzoate;

N-[3,5-Dichlorobenzyl]-N-hydroxyformamide;

N-[3,5-Dichloro-4-methoxybenzyl]-N-hydroxyformamide;

N-Hydroxy-N-(4-amino-3,5-dichlorobenzyl)formamide;

N-[3,5-Dichloro-4-(2-thiophen-2-ylethoxy)benzyl]-N-hydroxyformamide;

N-[3,5-Dichloro-4-(2-hydroxyethoxy)benzyl]-N-hydroxyformamide;

N-[3,5-Dichloro-4-(pyridin-4-ylmethoxy)-benzyl]-N-hydroxy-formamide;

N-[3,5-Dichloro-4-((S)-1-methyl-2,5-dioxo-pyrrolidin-3-yloxy)-benzyl]-N-hydroxy-formamide;

2-Butoxy-3-chloro-N-(2,3-dihydroxypropyl)-5-[(formylhydroxyamino)methyl]-benzamide;

N-{3,5-Dichloro-4-[2-(2-oxo-pyrrolidin-1-yl)-ethoxy]-benzyl}-N-hydroxy-formamide;

2-Butoxy-3-chloro-5-[(formyl-hydroxy-amino)-methyl]-benzoic acid methyl ester;

N-[3,5-Dichloro-4-(1-ethyl-butoxy)-benzyl]-N-hydroxy-formamide;

N-hydroxy-N-(3-iodo-5-methoxy-4-phenoxy-benzyl)-formamide;

N-(4-butoxy-3-iodo-5-methoxy-benzyl)-N-hydroxy-formamide;

N-(4-cyclohexyloxy-3,5-dichloro-benzyl)-N-hydroxy-formamide;

N-(2-Acetylaminoethyl)-2-butoxy-3-chloro-5-[(formylhydroxyamino)methyl]benzamide;

N-(4-butoxyl-3-chloro-5-hydroxy-benzyl)-N-hydroxy-formamide;

N-hydroxy-N-[3-iodo-5-methoxy-4-(2-methoxy-ethoxy)-benzyl]-formamide;

N-[3-Chloro-4-(3,4-dichloro-phenoxy)-5-methoxy-benzyl]-N-hydroxy-formamide;

N-[4-butoxy-2,3-dichloro-5-methoxy-benzyl]-N-hydroxy-formamide;

N-{2-Butoxy-5-[(formyl-hydroxy-amino)-methyl]-3-iodo-phenyl}-acetamide;

2-{2-Butoxy-5-[(formyl-hydroxy-amino)-methyl]-3-iodo-phenoxy}-N-methyl-acetamide and

N-(3-Chloro-5-methoxy-4-phenoxybenzyl)-N-hydroxyformamide.

3. A compound according to claim 1 selected from the group consisting of:

N-Hydroxy-N-[4-(4-hydroxyphenoxy)-3,5-diiodobenzyl]formamide;

N-[3,5-Dichloro-4-(4-methoxyphenoxy)benzyl]-N-hydroxyformamide;

N-(4-Butoxy-3,5-dichlorobenzyl)-N-hydroxyformamide;

N-(3-Chloro-5-methoxy-4-phenoxybenzyl)-N-hydroxyformamide;

N-(4-butoxy-3-chloro-5-methoxybenzyl)-N-hydroxy-formamide;

2-{2-Butoxy-3-chloro-5-[(formylhydroxyamino)methyl]phenoxy}-N-methyl acetamide and

N-(4-Butoxy-3-iodo-5-methylamino-benzyl)-N-hydroxy-formamide.

4. A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1 .

5. A method according to claim 4 , wherein the compound is selected from the group consisting of:

N-Hydroxy-N-(4-methoxy-3,5-dimethylbenzyl)formamide;

N-(3,5-Diisopropyl-4-methoxybenzyl)-N-hydroxyformamide; Methyl 2,6-dichloro-4-(N-formyl-N-hydroxyaminomethyl)benzoate;

N-[3,5-Dichlorobenzyl]-N-hydroxyformamide;

N-[3,5-Dichloro-4-methoxybenzyl]-N-hydroxyformamide;

N-Hydroxy-N-(4-amino-3,5-dichlorobenzyl)formamide;

N-[3,5-Dichloro-4-(2-thiophen-2-ylethoxy)benzyl]-N-hydroxyformamide;

N-[3,5-Dichloro-4(2-hydroxyethoxy)benzyl]-N-hydroxyformamide and

N-(3-Chloro-5-methoxy-4-phenoxybenzyl)-N-hydroxyformamide.

6. A method of treating a bacterial infection according to claim 5 selected from the group consisting of respiratory tract infection, and Gram+TPP.